查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1145990

胃氣球市場：COVID-19 的增長、趨勢、影響和預測（2022-2027 年）

Gastric Balloons Market - Growth, Trends, and Forecasts (2022 - 2027)
出版日期: | 出版商: Mordor Intelligence | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計胃球囊市場在預測期內的複合年增長率為 9.5%。

COVID-19 疫情對所研究的市場產生了重大影響，因為世界各國政府採取了社會疏離措施，醫院和醫療保健服務受到了嚴重限制。例如，2021 年 2 月發表的《當大流行病相撞：COVID-19 對兒童肥胖症的影響》發現，兒童肥胖症在美國的年輕人中已經上升到大流行水平，其中重症病例上升最快肥胖。被注意到已經被看到。還有人指出，肥胖的人有患嚴重 COVID-19 的風險，因為體重過重會降低個體的免疫反應。 COVID-19 流行期間肥胖患者的增加可能會促進分析期間的市場增長。因此，COVID-19 對所研究的市場產生了顯著影響。

此外，肥胖患病率的上升和對微創手術的需求不斷增加正在對所研究市場的增長產生積極影響。

根據聯合國 2022 年 3 月的文章，2022 年全球將有超過 10 億人肥胖，其中包括 6.5 億成年人、3.4 億青少年和 3900 萬兒童。這個數字還會增加。世界衛生組織預測，到 2025 年，大約 1.67 億人將因超重或肥胖而變得不健康。被診斷患有肥胖症並有糖尿病和高血壓等健康風險的患者可以選擇接受胃球囊手術。肥胖患病率上升是胃球囊市場的主要驅動因素。

此外，產品批准、發布、合作夥伴關係和收購預計將推動市場增長。例如，2020 年 7 月，Allurion Technologies 進入亞洲市場，在香港、馬來西亞和新加坡推出了 Elipse 胃氣球減肥計劃。向亞洲擴張，迄今為止，該地區獲得無創減肥治療的機會有限，預計該地區超過 10 億超重或肥胖人群將受益。預計此類舉措將進一步推動市場增長。

因此，由於上述因素，預計研究中的市場將在分析期間呈現增長。然而，報銷政策的不足以及與胃球囊相關的副作用和並發症可能會阻礙市場增長。

主要市場趨勢

預計三胃氣球市場將在預測期內佔據主導地位

三重胃氣球系統是一種非手術治療，可放置三個氣球以實現最佳減肥效果。 Ovalon Balloon 是唯一獲得 FDA 批准的三重胃氣球或設備，可幫助您減輕體重，它通過佔用您的胃部空間來發揮作用。 Ovalon 氣球通過吞下附在小軟管上的膠囊被輸送到胃部，並在專家領導的營養和鍛煉計劃中使用六個月。

肥胖是一種慢性疾病，其中過多的脂肪組織在體內積聚，從而對健康產生不利影響。根據世界衛生組織 (WHO) 2021 年 6 月更新的數據，到 2020 年，將有大約 3900 萬五歲以下兒童超重或肥胖。據報導，肥胖症在人群中呈上升趨勢，因此有望推動這一細分市場的增長。

批准和發布是該細分市場增長的主要驅動力。例如，2021 年 10 月，Spatz Medical 獲得了食品和藥物管理局對 Spatz3 胃氣球的批准，這是首批可調節胃氣球之一。預計這些批准將增加對胃球囊的需求並增加細分市場的增長。

因此，由於上述因素，預計三重胃氣球段在預測期內將出現增長。

預計在預測期內北美將主導胃球囊市場

北美的特點是肥胖發病率上升、老年人口不斷增長、該地區行業參與者的強大存在、更好的醫療保健基礎設施、公共和醫療保健行業對可用技術的看法、美國市場預計將主導市場由於參與者高度集中等因素。

2022 年 1 月發表的研究論文《社區居住成人 1 年和 3 歲肥胖發病率：一項基於人群的研究》發現，美國有 40,390 人參與了該研究並有後續數據。大多數其中40至69歲的成年人（47.5%）和女性（59.8%），其中21,379人屬於超重組。肥胖的患病率在 1 年時為 7%，在 3 年時為 16%。另據報導，40 至 69 歲的男性和 20 至 39 歲的女性分別在 1 年和 3 年後發生肥胖的比率最高。預計該地區肥胖人數的增加將提振對治療性胃球囊手術的需求，從而推動該地區的市場增長。

越來越多的產品發布、合作夥伴關係、合併、收購和政府舉措（尤其是在美國）正在推動市場增長。例如，2021 年 3 月，Apollo Endosurgery, Inc. 宣布了一項適應症，用於治療基礎代謝指數 (BMI) 為 30-40 kg/m2 的肝纖維化非切口非酒精性脂肪性肝炎 (NASH) 患者. orbera 胃內氣球已獲得美國食品和藥物管理局的突破性設備指定。因此，預計這樣的推出將增加該地區胃氣球的使用並促進市場增長。

此外，2021 年 1 月，ReShape Lifesciences Inc. 與 Obalon Therapeutics, Inc. 簽訂了合併協議。根據協議條款，Obalon 更名為 ReShape Lifesciences Inc.。兩家公司都生產減肥技術和解決方案。預計合併將導致該地區研究市場的增長。

因此，由於上述因素，預計北美市場將擴大。

競爭格局

由於存在少數在全球和地區運營的公司，胃球囊市場適度整合。競爭格局包括對具有市場份額的知名國際和本地公司的分析。其中包括 ReShape Lifesciences, Inc.、Allurion Technologies, Inc.、Apollo Endosurgery, Inc.、Districlass Medical、Helioscopie Medical Implants 和 Silimed, Inc.。 LEXEL S.R.L.、Medispar cvba、Spatz Cosmeceutical Inc.、ENDALIS 等。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場動態

  • 市場概覽
  • 市場驅動力
    • 肥胖患病率上升
    • 對微創手術的需求增加
  • 市場製約因素
    • 兌換政策不佳
    • 與胃膨脹有關的副作用或併發症
  • 波特五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：100 萬美元）

  • 按產品類型
    • 單胃氣球
    • 雙氣化氣球
    • 三重胃氣球
  • 通過填充材料
    • 充滿鹽水的氣球
    • 充氣氣球
  • 按插入方式
    • 內窺鏡
    • 口語
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海合會
      • 南非
      • 其他中東
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第 6 章競爭格局

  • 公司簡介
    • Reshape Lifesciences Inc
    • Allurion Technologies Inc.
    • Apollo Endosurgery, Inc.
    • Districlass Medical SA
    • Helioscopie Medical Implants
    • Silimed, Inc.
    • Medispar cvba
    • Spatz Cosmeceutical Inc.
    • ENDALIS
    • LEXEL S.R.L

第7章 市場機會今後動向

簡介目錄
Product Code: 67636

The gastric balloon market is expected to register a CAGR of 9.5% over the forecast period.

The COVID-19 outbreak had a significant impact on the studied market as hospital and healthcare services were significantly reduced due to social distancing measures taken by governments across the world. For instance, an article titled "When Pandemics Collide: The Impact of COVID-19 on Childhood Obesity" published in February 2021 indicated that the disease of childhood obesity had risen to pandemic levels in United States youth with the fastest rise seen in severe obesity. The article also indicated that obese people were at risk for severe COVID-19, as excess weight decreases an individual's immune response. The increase in obesity cases during the COVID-19 pandemic is likely to enhance the market growth in the analysis period. Hence, COVID-19 had a pronounced impact on the studied market.

In addition, the rising prevalence of obesity and increasing demand for minimally invasive surgeries are actively affecting the growth of the studied market.

According to United Nations March 2022 article, more than one billion people worldwide are obese in 2022, including 650 million adults, 340 million adolescents, and 39 million children and the numbers are likely to rise. The World Health Organization predicted that by 2025, roughly 167 million people are projected to become less healthy due to being overweight or obese. Patients diagnosed with obesity and associated health risks such as diabetes and hypertension are given the option to undergo a gastric balloon procedure. The rising prevalence of obesity is the key driving factor in the gastric balloon market.

Furthermore, product approvals, launches, partnerships, and acquisitions are expected to propel market growth. For instance, in July 2020 Allurion Technologies expanded into the Asian market with the launch of the Elipse Gastric Balloon Weight Loss Program in Hong Kong, Malaysia, and Singapore. Over 1 billion overweight or obese people in the region were expected to benefit from the company's entry into Asia, a region that has previously had limited access to non-invasive weight loss treatments. Such initiatives are projected to further boost the market growth.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, poor reimbursement policies and side effects or complications associated with gastric balloons may impede the market growth.

Key Market Trends

Triple Gastric Balloons Segment is Expected to to Dominate Over the Forecast Period

A triple gastric balloon system is a non-surgical treatment in which three balloons are placed for optimal weight loss. Obalon balloon is the only Food and Drug Administration-approved triple gastric balloon or device that helps in weight loss and works by taking up space in the stomach. Obalon balloon is delivered into the stomach by swallowing a capsule connected to a small bendable tube for six months combined with a professionally supervised nutrition and exercise program.

Obesity is a chronic disease characterized by excessive adipose tissue accumulation in the body, resulting in adverse health effects. Data provided by World Health Organization (WHO) updated in June 2021 indicated that there were around 39 million children under the age of five, who were overweight or obese in the year 2020. It also reported that there is steep rise in obesity among the population and thus it is expected to boost the segment's growth.

The approvals and launches are primary drivers of the segment's growth. For instance, in October 2021, Spatz Medical received the Food and Drug Administration approval for the Spatz3 Gastric Balloon, one of the first adjustable gastric balloons. These approvals are projected to increase the demand for gastric balloons and augment segment growth.

Therefore, owing to the above mentioned factors, the triple gastric balloons segment is expected to show growth over the forecast period.

North America is Expected to Dominate the Gastric Balloons Market Over the Forecast Period

North America is expected to dominate the market owing to factors such as the rising incidence of obesity, growing geriatric population, the strong presence of industry players in the region, better healthcare infrastructure, awareness among people and healthcare industry stakeholders about available technologies, and the high concentration of market players in the United States.

The research article titled "Incidence of Obesity at 1 and 3 Years Among Community-Dwelling Adults: A Population-Based Study" published in January 2022 stated that the majority of the 40,390 people in the United States who were part of the study and had follow-up data were adults aged 40 to 69 (47.5%), female (59.8%), and 21,379 (52.8%) of them fell into the overweight weight group. Obesity prevalence was 7% after one year and 16% after three years of follow-up. It also reported that the age groups of males aged 40 to 69 and women aged 20 to 39 had the largest percentages of those who developed obesity after one and three years of follow-up respectively. The increase in obesity in the region is expected to increase the demand for gastric balloon procedures for treatment and thus boost the market growth in the region.

The increasing product launches, partnerships, mergers, acquisitions, and government initiatives particularly in the United States are leading to an increase in market growth. For instance, in March 2021, Apollo Endosurgery, Inc. received a breakthrough device designation from the United States Food and Drug Administration for the orbera intragastric balloon, with a focus on the indication for use in treating patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis and a basal metabolic index (BMI) between 30 and 40 kg/m2. Hence, such launches are expected to increase the usage of gastric balloons in the region and augment market growth.

Additionally, in January 2021 ReShape Lifesciences Inc. signed a merger agreement with Obalon Therapeutics, Inc. Under the agreement terms, Obalon was renamed ReShape Lifesciences Inc. Both companies are involved in producing weight-loss technologies and solutions. The merger is anticipated to lead to growth in the studied market in the region.

Therefore, owing to the above-mentioned factors, the growth of the studied market is anticipated in the North America region.

Competitive Landscape

The Gastric balloon market is moderately consolidated due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some of the companies are ReShape Lifesciences, Inc., Allurion Technologies, Inc., Apollo Endosurgery, Inc., Districlass Medical, Helioscopie Medical Implants, Silimed, Inc. , LEXEL S.R.L, Medispar cvba, and Spatz Cosmeceutical Inc., and ENDALIS among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Obesity
    • 4.2.2 Increasing Demand for Minimally Invasive Surgeries
  • 4.3 Market Restraints
    • 4.3.1 Poor Reimbursement Policies
    • 4.3.2 Side Effects or Complications Associated with Gastric Balloons
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type
    • 5.1.1 Single Gastric Balloons
    • 5.1.2 Dual Gastric Balloons
    • 5.1.3 Triple Gastric Balloons
  • 5.2 By Filling Material
    • 5.2.1 Saline Filled Balloons
    • 5.2.2 Gas Filled Balloons
  • 5.3 By Insertion Method
    • 5.3.1 Endoscopic
    • 5.3.2 Oral
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Reshape Lifesciences Inc
    • 6.1.2 Allurion Technologies Inc.
    • 6.1.3 Apollo Endosurgery, Inc.
    • 6.1.4 Districlass Medical SA
    • 6.1.5 Helioscopie Medical Implants
    • 6.1.6 Silimed, Inc.
    • 6.1.7 Medispar cvba
    • 6.1.8 Spatz Cosmeceutical Inc.
    • 6.1.9 ENDALIS
    • 6.1.10 LEXEL S.R.L

7 MARKET OPPORTUNITIES AND FUTURE TRENDS